GRIK4 polymorphism and its association with antidepressant response in depressed patients: A meta-analysis

Pharmacogenomics

Volumn 15, Issue 11, 2014, Pages 1451-1459

  Kawaguchi, Daniel M ^a   Glatt, Stephen J ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

antidepressant; glutamate; GRIK4 polymorphism; major depressive disorder; meta analysis; predictor; treatment response

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; GRIK4 PROTEIN, HUMAN; KAINIC ACID RECEPTOR;

ACCURACY; ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DRUG RESPONSE; EFFECT SIZE; FEMALE; GENE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; GRIK4 GENE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PHARMACOGENOMICS; PUBLISHING; RANDOM EFFECTS MODEL; RELIABILITY; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL MODEL; TREATMENT OUTCOME; ALLELE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS;

ALLELES; ANTIDEPRESSIVE AGENTS; DEPRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; RECEPTORS, KAINIC ACID;

EID: 84907924359     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.96     Document Type: Article

References (19)

1. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer. Adherence 6, 369-388 (2012).
2. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR.D: implications for clinical practice. Am. J. Psychiatry 163(1), 28-40 (2006).
3. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-Analysis of data submitted to the Food and Drug Administration. PLoS Med. 5(2), e45 (2008).
4. Vohringer PA, Ghaemi SN. Solving the antidepressant efficacy question: effect sizes in major depressive disorder. Clin. Ther. 33(12), B49-B61 (2011).
5. Hasler G, Van Der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-Aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch. Gen. Psychiatry 64(2), 193-200 (2007).
6. Sanacora G, Gueorguieva R, Epperson CN, et al. Subtype-specific alterations of gamma-Aminobutyric acid and glutamate in patients with major depression. Arch. Gen. Psychiatry 61(7), 705-713 (2004).
7. Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS. Glutamate receptor antagonists as fast-Acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Ann. Rev. Pharmacol. Toxicol. 54, 119-139 (2014).
8. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 62(1), 63-77 (2012).
9. Paddock S, Laje G, Charney D, et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR. D cohort. Am. J. Psychiatry 164(8), 1181-1188 (2007).
10. Perlis RH, Fijal B, Dharia S, Heinloth AN, Houston JP. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-Treated patients. Biol. Psychiatry 67(11), 1110-1113 (2010).
11. Serretti A, Chiesa A, Crisafulli C, et al. Failure to replicate influence of GRIK4 and GNB3 polymorphisms on treatment outcome in major depression. Neuropsychobiology 65(2), 70-75 (2012).
12. Horstmann S, Lucae S, Menke A, et al. Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment. Neuropsychopharmacology 35(3), 727-740 (2010).
13. Pu M, Zhang Z, Xu Z, et al. Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response. Pharmacogenomics 14(3), 277-288 (2013).
14. GENDEP Investigators, MARS Investigators, STARD Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-Analysis of three genome-wide pharmacogenetic studies. Am. J. Psychiatry 170(2), 207-217 (2013).
15. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control. Clin. Trials 7(3), 177-188 (1986).
16. Woolf B. On estimating the relation between blood group and disease. Ann. Hum. Genet. 19, 251-253 (1955).
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 315(7109), 629-634 (1997).
18. Drago A, Giegling I, Schafer M, et al. AKAP13, CACNA1, GRIK4 and GRIA1 genetic variations may be associated with haloperidol efficacy during acute treatment. Eur. Neuropsychopharmacol. 23(8), 887-894 (2013).
19. Pickard BS, Malloy MP, Christoforou A, et al. Cytogenetic and genetic evidence supports a role for the kainate-Type glutamate receptor gene, GRIK4, in schizophrenia and bipolar disorder. Mol. Psychiatry 11(9), 847-857 (2006